According to reports, human embryonic stem cells can differentiate into various cells and tissues in adults, so they have great potential for treating major diseases in humans. But the current development of stem cell therapy
One of the main bottlenecks is the immune rejection after transplantation.

The key to the success of the new research is the development of a "humanized" experimental mouse. Xu Yang said that although there are many similarities between the mouse and human immune systems, they also have many different places, so the strategies for preventing immune rejection in the mouse model mostly fail in human clinical trials. To solve this problem, ELISA kits transplant hematopoietic stem cells from human embryonic thymus and embryonic liver into immunodeficient mice to produce "humanized" experimental mice that effectively reject the differentiation of allogeneic human embryonic stem cells. Tissue and cells.

Using "humanized" experimental mice, they tested various immunosuppressive molecules and their combinations, and found that CTLA4-lg and PD-L1 work very well, the former being approved by the US Food and Drug Administration. Rheumatoid arthritis is a therapeutic drug, and the latter is a protein known to play an important role in tumor-induced immune tolerance.

With the continuous advancement of science, people will only become more and more effective in fighting various diseases in the future, but as much as possible, the speed of virus mutation is also accelerating. For our usual habits, we still have to pay attention to it in some aspects.